| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Christopher Ross MacLeod is Director at ZOMDF. Christopher Ross MacLeod's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $13K at current prices.
Net of sales, the ZOMDF filings show accumulation of 136,600 shares.
Christopher Ross MacLeod has 7 Form 4 filings on record from July 2020 to November 2025, all as Director at Zomedica (ZOMDF), 2020–2025.
The 7 reported transactions were 5 option or other derivative awards, 1 open-market purchase and 1 open-market sale.
Counted by filing, the open-market trades come to 1 purchase worth about $8K and 1 sale worth about $7K.
The only open-market purchase was 143,000 shares of ZOMDF at an average $0.06 on March 17, 2025, about $8K.
The only open-market sale was 6,400 shares of ZOMDF at an average $1.10 on February 3, 2021, about $7K.